行情

BLUE

BLUE

bluebird bio
NASDAQ

实时行情|Nasdaq Last Sale

87.26
-2.46
-2.74%
盘后: 87.26 0 0.00% 17:44 01/24 EST
开盘
91.42
昨收
89.72
最高
91.42
最低
86.75
成交量
74.96万
成交额
--
52周最高
163.43
52周最低
71.42
市值
48.27亿
市盈率(TTM)
-6.7174
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLUE 新闻

  • UPDATE 1-Novartis, GBT sickle cell drugs too expensive, draft U.S. report says
  • Reuters.1天前
  • FDA Puts GlaxoSmithKline's Blood Cancer Drug In the Fast Lane
  • MotleyFool.com.4天前
  • 2 Biotech Stocks to Watch In 2020
  • MotleyFool.com.01/17 14:00
  • Bluebird bio launches Zynteglo for TDT in Germany
  • Seeking Alpha - Article.01/13 11:38

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

BLUE 简况

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
展开

Webull提供bluebird bio Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。